Deals·October 19, 2026 at 7:08 AM EDT·2 sources
Roche does $400M upfront, $15B deal with China's Hansoh
acquisition, log scale$15B
$100M$1B$10B$100B
What happened
- Roche signed a cross-border collaboration with China’s Hansoh.
- Roche will pay $400 million upfront, with potential total value of $15 billion in biobucks.
Upfront payment
$400 million
Potential total value
$15 billion
Why it matters
The deal highlights Roche’s increased focus on Chinese drug discovery and development and is significant for healthcare dealmakers tracking cross-border pharma collaborations.
Deal terms
acquisition
Roche → Hansoh
Value
$15B
Read more on YouBank
The Newsroom, ranked for your desk
About ninety free sources every ten minutes, one story per event, read for you: bankers, investors, operators and students each get their own desk. Free to start.
Timeline
- First reported by Endpoints NewsOct 19Roche does $400M upfront, $15B deal with China's Hansoh
- The Wall Street Journal reportsOct 19Roche Partners With China’s Hansoh in Deal That Could Top $15 Billion
Who is involved
acquiringRoche does $400M upfront, $15B deal with China's HansohHansohtargetRochebuyer
CompanyThe deal
Sources (2)
- Endpoints NewsOct 19Roche does $400M upfront, $15B deal with China's Hansoh
- The Wall Street JournalOct 19Roche Partners With China’s Hansoh in Deal That Could Top $15 Billion
Read more on YouBank
The Newsroom, ranked for your desk
About ninety free sources every ten minutes, one story per event, read for you: bankers, investors, operators and students each get their own desk. Free to start.
- Why it matters to youEvery story matched to your watchlist, your contacts and your pipeline.
- Follow developing storiesAn alert, and a push, the moment a story you follow moves.
- Your briefing, read aloudA few minutes each morning with a chapter per story.
- Brief modeSwipe through the day, a 20-second card each.